Key facts
- This page summarizes OrbiMed Israel BioFund GP Limited Partnership's Form 4 filing for BiomX Inc. (PHGE).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 May 2024, 16:39.
OrbiMed Israel BioFund GP Limited Partnership - 15 May 2024 Form 4 Insider Report for BiomX Inc. (PHGE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PHGE
- Reported as of
- 15 May 2024
- Net transaction value
- +$2,255,140
- SEC form
- 4
- Accepted by SEC
- 20 May 2024, 16:39:38 UTC
- Prior SEC filing
- 19 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
OrbiMed Israel BioFund GP Limited Partnership filed Form 4 for BiomX Inc. (PHGE) on 20 May 2024.
Change
- Previous filing in this sequence was filed on 19 Mar 2024.
- Current net transaction value: +$2,255,140.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHGE
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $2,264,420
- Shares
- +9,280,408
- Change %
- +205%
- Price
- $0.2440
- Shares after
- 13,797,997
- Date
- 15 May 2024
- Ownership
- See footnotes
- Footnotes
- F2, F3
PHGE
transaction
Common Stock
Sale
- Transaction value
- $9,280
- Shares
- -24,344
- Change %
- -0.18%
- Price
- $0.3812
- Shares after
- 13,773,653
- Date
- 15 May 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHGE
transaction
Derivative
Warrants (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -9,280,408
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 May 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 9,280,408
- Exercise price
- $0.2440
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On May 15, 2024, OrbiMed Israel Partners Limited Partnership ("OIP") exercised pre-funded warrants ("Warrants") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory "profits" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions.
Footnote F2
These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
Footnote F3
Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.